| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	BMO Capital analyst Evan David Seigerman upgrades Replimune Group (NASDAQ:REPL) from Underperform to Market Perform and rais...
																	
																	HC Wainwright & Co. analyst Robert Burns upgrades Replimune Group (NASDAQ:REPL) from Neutral to Buy and announces $12 pr...
																	JP Morgan analyst Anupam Rama upgrades Replimune Group (NASDAQ:REPL) from Underweight to Neutral and announces $11 price tar...
																	
																	Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory update.
																	Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perform to Outperform and raises ...